Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | Early results of mevrometostat & enzalutamide in mCRPC at ASCO GU 2025

Michael Schweizer • 14 Feb 2025
GU Cancers 2025
Genitourinary Cancer Prostate Cancer Enzalutamide Mevrometostat

Michael Schweizer, MD, Fred Hutchinson Cancer Center, Seattle, WA, discusses findings from a randomized dose-expansion study (NCT03460977) of mevrometostat, an EZH2 inhibitor, with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). The combination demonstrated improved radiographic progression-free survival and prostate-specific antigen response compared to enzalutamide alone, with a manageable safety profile. Further research is needed to refine dosing strategies and confirm clinical benefits. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Schweizer

MEVPRO trials: investigating EZH2 inhibitors in mCRPC
0:41
MEVPRO trials: investigating EZH2 inhibitors in mCRPC
Michael Schweizer • 14 Feb 2025
MEVPRO-2: mevrometostat and enzalutamide in patients with ARPI-naïve mCRPC
0:33
MEVPRO-2: mevrometostat and enzalutamide in patients with ARPI-naïve mCRPC
Michael Schweizer • 14 Feb 2025
Mevrometostat and enzalutamide in mCRPC: gene expression and EZH2 modulation
0:55
Mevrometostat and enzalutamide in mCRPC: gene expression and EZH2 modulation
Michael Schweizer • 14 Feb 2025

Related Videos

Advances in next-generation PSMA-targeted radioligand therapy
2:09
Advances in next-generation PSMA-targeted radioligand therapy
Jeremie Calais • 1 Jun 2026
Toxicity considerations with actinium PSMA radioligand therapy in prostate cancer
2:22
Toxicity considerations with actinium PSMA radioligand therapy in prostate cancer
Jeremie Calais • 1 Jun 2026
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
The content of VJOncology is intended for healthcare professionals